Single‐Microglia Transcriptomic Transition Network‐based Prediction and Real‐world Patient Data Validation Identifies Ketorolac as a Repurposable Drug for Alzheimer’s Disease
This study offers insights into pathobiology of AD-relevant microglial subtypes and identifies ketorolac as a potential anti-inflammatory treatment for AD.
Authors
- Michal Rosen‐Zvi (ORCID: https://orcid.org/0000-0001-7616-9724)
- Yuan Hou (ORCID: https://orcid.org/0000-0002-3900-6122)
- Yishai Shimoni (ORCID: https://orcid.org/0000-0002-4364-4207)
- Ehud Karavani (ORCID: https://orcid.org/0000-0002-0187-5437)
- Feixiong Cheng (ORCID: https://orcid.org/0000-0002-1736-2847)
- Michael M. Danziger (ORCID: https://orcid.org/0000-0002-2674-0109)
- Andrew A. Pieper (ORCID: https://orcid.org/0000-0001-6299-6577)
- Yadi Zhou (ORCID: https://orcid.org/0000-0002-6049-0545)
- Fei Wang (ORCID: https://orcid.org/0000-0001-9459-9461)
- Jianying Hu
- Zhenxing Xu (ORCID: https://orcid.org/0009-0001-9566-5341)
- Chengxi Zhang (ORCID: https://orcid.org/0000-0003-2419-9467)
- James B. Leverenz
- Jielin Xu
- Jeffrey L. Cummings
Institutions
- Cleveland Clinic (US)
- IBM (United States) (US)
- Cornell University (US)
- Lou Ruvo Brain Institute (US)
- IBM Research - Haifa (IL)
- Weill Cornell Medicine (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.089596
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00